Astrazeneca (AZN) Enterprise Value (2009 - 2026)
Astrazeneca (AZN) posted quarterly Enterprise Value of -$5.0 billion for Q2 2026, up 29.54% year-over-year from -$3.8 billion in Q2 2025, and up 49.57% quarter-over-quarter from -$9.9 billion in Q1 2026.
Astrazeneca (AZN) Enterprise Value (2009 - 2026) Analysis & Trends
Astrazeneca's Enterprise Value history runs 18 years deep, the most recent figure standing at -$5.0 billion for Q2 2026.
- In Q2 2026, Enterprise Value rose 29.54% year-over-year to -$5.0 billion; the TTM figure through Jun 2026 stood at -$5.0 billion (up 29.54% YoY), while the FY2025 annual figure was -$5.7 billion, down 3.23% from the prior year.
- Enterprise Value for Q2 2026 stood at -$5.0 billion, up from -$9.9 billion in the prior quarter.
- The five-year high for Enterprise Value was -$5.0 billion in Q2 2026, with the low at -$10.0 billion in Q3 2025.
- The 5-year median for Enterprise Value is -$6.6 billion (2023), against an average of -$7.0 billion.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value jumped 64.37% in 2022, then tumbled 53.06% in 2025.
- Astrazeneca's Enterprise Value stood at -$6.4 billion in 2022, then increased by 6.97% to -$5.9 billion in 2023, then increased by 6.23% to -$5.6 billion in 2024, then declined by 3.23% to -$5.7 billion in 2025, then gained by 13.45% to -$5.0 billion in 2026.
- Business Quant data shows AZN's Enterprise Value at -$5.0 billion in Q2 2026, -$9.9 billion in Q1 2026, and -$5.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.98 Bn |
| Mar 31, 2026 | -9.87 Bn |
| Dec 31, 2025 | -5.75 Bn |
| Sep 30, 2025 | -10.05 Bn |
| Jun 30, 2025 | -7.06 Bn |
| Mar 31, 2025 | -6.77 Bn |
| Dec 31, 2024 | -5.57 Bn |
| Sep 30, 2024 | -6.57 Bn |
| Jun 30, 2024 | -8.44 Bn |
| Mar 31, 2024 | -9.35 Bn |
| Dec 31, 2023 | -5.94 Bn |
| Sep 30, 2023 | -6.08 Bn |
| Jun 30, 2023 | -6.71 Bn |
| Mar 31, 2023 | -7.37 Bn |
| Dec 31, 2022 | -6.38 Bn |
| Sep 30, 2022 | -5.49 Bn |
| Jun 30, 2022 | -5.92 Bn |
| Mar 31, 2022 | -6.92 Bn |
| Dec 31, 2021 | -6.39 Bn |
| Sep 30, 2021 | -8.45 Bn |